02.18.10
Genzyme 4Q
4Q Revenues: $1.1 billion (-8%)
4Q Earnings: $23.2 million (earnings were $86.7 million in 4Q08)
FY Revenues: $4.5 billion (-2%)
FY Revenues: $422.3 million (flat)
Comments: Genetic Diseases revenue was $315.1 million in the quarter (-44%) due to product supply interruption. Cerezyme sales were $105.4 million (-66%), and Fabrazyme sales were down 54% to $58.0 million. Cardiometabolic and Renal sales in the quarter were $259.2 million (+7%). Renagel and Renvela sales were $178.9 million (+6%). Hematologic Oncology revenue was $108.3 million in the quarter (+154%). R&D expenses were down 36% in the quarter to $228.5 million.
4Q Revenues: $1.1 billion (-8%)
4Q Earnings: $23.2 million (earnings were $86.7 million in 4Q08)
FY Revenues: $4.5 billion (-2%)
FY Revenues: $422.3 million (flat)
Comments: Genetic Diseases revenue was $315.1 million in the quarter (-44%) due to product supply interruption. Cerezyme sales were $105.4 million (-66%), and Fabrazyme sales were down 54% to $58.0 million. Cardiometabolic and Renal sales in the quarter were $259.2 million (+7%). Renagel and Renvela sales were $178.9 million (+6%). Hematologic Oncology revenue was $108.3 million in the quarter (+154%). R&D expenses were down 36% in the quarter to $228.5 million.